PIPEX PHARMACEUTICALS, INC.

Form 8-K May 02, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 1, 2008

Pipex Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware 01-12584

13-3808303

(State or other jurisdiction of

(Commission

Identification Number)

(IRS Employer

incorporation) File Number)

3930 Varsity Drive

Ann Arbor, MI 48108

(Address of principal executive offices) (Zip Code)

(734) 332-7800

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- O Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- O Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- O Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- O Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PIPEX PHARMACEUTICALS, INC. - Form 8-K

Item 8.01 Other Events.

On May 1, 2008, the Registrant was informed that the manuscript describing the results of an 80 patient, randomized, double-blind, placebo-controlled clinical trial of oral zinc-monocysteine (oral Z-monocys) for the treatment of dry age-related macular degeneration (AMD) has completed the peer review process and has been accepted for publication by a peer reviewed medical ophthalmology journal. The Registrant had previously disclosed that oral Z-monocys therapy had demonstrated statistically significant improvement in visual acuity and other key markers of retinal function.

SIGNATURE

Dated: May 1, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PIPEX PHARMACEUTICALS, INC.

By: /s/ Steve H. Kanzer

Steve H. Kanzer, Chairman & CEO